Vivek Subbiah shared his recent article on LinkedIn:

“Pleased to share the pre-proof version of the editorial commentary just published ESMO – European Society for Medical Oncology flagship journal Annals of Oncology.

Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology.”

Tittle: Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology

Author: Vivek Subbiah

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (Vivek Subbiah USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.